B. Forsythe (Chicago, US)
Rush University Medical CenterPresenter Of 1 Presentation
P221 - The Effect of Bone Marrow Aspirate Concentrate Augmentation on ACL Reconstruction Allograft Volume and PROMs
Abstract
Purpose
Prior studies have correlated MRI-calculated tendon volume with biomechanical properties of ACL allografts in porcine models. Bone marrow aspirate concentrate (BMAC) has been shown to improve biomechanical graft strength in other animal studies. The purpose of this study was to assess the clinical effects of bone marrow aspirate concentrate (BMAC) on ACL bone-tendon-bone (BTB) allograft volume and PROMs.
Methods and Materials
The study population included a convenience sample of 66 patients from an IRB-approved, double-blinded, randomized control trial comparing patients undergoing ACL reconstruction (ACLR) with BTB allograft±BMAC. All patients received 3-month and 9-month knee MRIs. The primary outcome was tendon volume at 9 months, with a secondary outcome of change in tendon volume between 3-9 months. KOOS-Jr, Tegner activity scale, and IKDC were obtained pre-operatively and at 1 year.
Results
The final analysis included 32 BMAC study patients (BMAC volume=2.42±0.90 mL, soak time=17.83±.15 mins) and 34 control patients. Baseline demographics, physical exam features, and PROs did not vary between groups. Average 9-month tendon volume was 773±280 mm3 in BMAC patients and 743±224 mm3 in controls (P=0.634). Mean change in tendon volume between 3-9 months was 1±175 mm3 in BMAC patients and -21±120 mm3 in controls (P=0.552). Tendon volume was not associated with KOOS-Jr (beta=7.26 mm3/point, 95 % Confidence Interval [CI]=-13.21-27.72, P=0.476), Tegner (beta=-0.53 mm3/point, 95% CI=-2.40-1.45, P=0.596), or IKDC (beta=5.18 mm3/point, 95% CI=-10.59-20.95, P=0.513). There was a nonsignificant, negative correlation between tendon volume and KT-1000 translation (beta=-0.56 mm3/cm, 95% CI=-1.15-0.04, P=0.065).
Conclusion
In this study, BMAC did not affect tendon volume at 9 months after ACLR. PRO-scores were not significantly associated with tendon volume. Translational studies are warranted to better elucidate the relationship between BMAC augmentation, PRO scores, and tendon volume in ACL allograft reconstruction.
Presenter Of 1 Presentation
P221 - The Effect of Bone Marrow Aspirate Concentrate Augmentation on ACL Reconstruction Allograft Volume and PROMs
Abstract
Purpose
Prior studies have correlated MRI-calculated tendon volume with biomechanical properties of ACL allografts in porcine models. Bone marrow aspirate concentrate (BMAC) has been shown to improve biomechanical graft strength in other animal studies. The purpose of this study was to assess the clinical effects of bone marrow aspirate concentrate (BMAC) on ACL bone-tendon-bone (BTB) allograft volume and PROMs.
Methods and Materials
The study population included a convenience sample of 66 patients from an IRB-approved, double-blinded, randomized control trial comparing patients undergoing ACL reconstruction (ACLR) with BTB allograft±BMAC. All patients received 3-month and 9-month knee MRIs. The primary outcome was tendon volume at 9 months, with a secondary outcome of change in tendon volume between 3-9 months. KOOS-Jr, Tegner activity scale, and IKDC were obtained pre-operatively and at 1 year.
Results
The final analysis included 32 BMAC study patients (BMAC volume=2.42±0.90 mL, soak time=17.83±.15 mins) and 34 control patients. Baseline demographics, physical exam features, and PROs did not vary between groups. Average 9-month tendon volume was 773±280 mm3 in BMAC patients and 743±224 mm3 in controls (P=0.634). Mean change in tendon volume between 3-9 months was 1±175 mm3 in BMAC patients and -21±120 mm3 in controls (P=0.552). Tendon volume was not associated with KOOS-Jr (beta=7.26 mm3/point, 95 % Confidence Interval [CI]=-13.21-27.72, P=0.476), Tegner (beta=-0.53 mm3/point, 95% CI=-2.40-1.45, P=0.596), or IKDC (beta=5.18 mm3/point, 95% CI=-10.59-20.95, P=0.513). There was a nonsignificant, negative correlation between tendon volume and KT-1000 translation (beta=-0.56 mm3/cm, 95% CI=-1.15-0.04, P=0.065).
Conclusion
In this study, BMAC did not affect tendon volume at 9 months after ACLR. PRO-scores were not significantly associated with tendon volume. Translational studies are warranted to better elucidate the relationship between BMAC augmentation, PRO scores, and tendon volume in ACL allograft reconstruction.